Contineum Therapeutics, Inc.
CTNMNasdaqCIK 1855175HealthcareFiscal year ends Dec 31
Reports and events: 41 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-09-1420:07 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-26-061834 |
| 2026-07-3020:11 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001628280-26-051054 |
| 2026-07-3020:08 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-051051 |
| 2026-07-1320:15 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001628280-26-048023 |
| 2026-06-2620:48 ET | 8-K | 5.07 Shareholder vote results | 0001628280-26-045804 |
| 2026-05-0520:24 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001628280-26-030614 |
| 2026-05-0520:09 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001628280-26-030522 |
| 2026-04-3020:08 ET | DEF 14A | Proxy statementPeriod 2026-06-26 | 0001628280-26-028881 |
| 2026-04-3020:07 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-26-028876 |
| 2026-03-0521:09 ET | 10-K | Annual reportPeriod 2025-12-31 | 0001628280-26-015165 |
| 2026-03-0521:06 ET | 8-K | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001628280-26-015159 |
| 2026-01-2621:06 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001437749-26-002072 |
| 2025-12-1521:05 ET | 8-K | 1.01 Entry into a material agreement; 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-25-037842 |
| 2025-12-1121:01 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-25-037547 |
| 2025-11-2021:07 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-25-035860 |
| 2025-10-3020:13 ET | 10-Q | Quarterly reportPeriod 2025-09-30 | 0001437749-25-032427 |
| 2025-10-3020:09 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-25-032422 |
| 2025-09-1812:16 ET | 8-K | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-25-029349 |
| 2025-08-0520:13 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0001437749-25-024852 |
| 2025-08-0520:08 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-25-024849 |
| 2025-06-2620:07 ET | 8-K | 5.07 Shareholder vote results | 0001437749-25-021343 |
| 2025-05-1420:44 ET | 8-K | 2.02 Results of operations; 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-25-016877 |
| 2025-05-1420:08 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0001437749-25-016835 |
| 2025-04-2920:07 ET | DEF 14A | Proxy statementPeriod 2025-06-26 | 0001437749-25-013528 |
| 2025-04-2820:10 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001437749-25-013334 |
| 2025-03-1720:07 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001437749-25-007998 |
| 2025-03-0621:10 ET | 10-K | Annual reportPeriod 2024-12-31 | 0001437749-25-006458 |
| 2025-03-0621:08 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-25-006457 |
| 2024-11-0621:10 ET | 10-Q | Quarterly reportPeriod 2024-09-30 | 0001437749-24-033616 |
| 2024-11-0621:08 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-24-033614 |
| 2024-08-1416:46 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0001437749-24-026680 |
| 2024-08-1416:19 ET | 8-K/A | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001437749-24-026664 |
| 2024-08-1320:10 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-24-026385 |
| 2024-06-2420:11 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001437749-24-021083 |
| 2024-05-3121:10 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001437749-24-018934 |
| 2024-05-2020:09 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001437749-24-017651 |
| 2024-05-1621:01 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0001437749-24-017320 |
| 2024-05-1620:08 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001437749-24-017293 |
| 2024-04-0920:49 ET | 8-K | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001193125-24-090917 |
| 2024-04-0112:41 ET | S-1/A | Registration statement, amended | 0001193125-24-082755 |
| 2024-03-1521:04 ET | S-1 | Registration statement | 0001193125-24-069256 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:06 ET. Listed shows no prices and gives no investment advice.